New, sophisticated drugs did not move the needs on hearts attacks, strokes: what this teaches us
Recent clinical trials for drugs targeting Lipoprotein(a) and C-Reactive Protein have failed to reduce heart attacks and strokes, despite these biomarkers being recently endorsed as critical risk factors by major cardiology organizations. The findings suggest that while these markers are valid indicators of heart disease risk, current pharmaceutical interventions may not effectively alter patient outcomes.
Why it matters
This highlights a significant gap in cardiovascular medicine where clinical guidelines and diagnostic testing have outpaced the efficacy of available drug therapies, potentially leading to unnecessary patient anxiety and treatment costs.
In March this year, the American College of Cardiology (ACC) and the American Heart Association (AHA), both globally recognised premier organisations in cardiovascular medicine, handed down their newest dyslipidemia guideline, and gave universal Lipoprotein(a) screening in every adult a ‘Class I’ recommendation -- the strongest tier there is. The High-Sensitivity C-Reactive Protein (hsCRP) test got a lighter endorsement: checked selectively, alongside coronary calcium scoring, to sharpen risk estimates when they’re uncertain. These two long-debated biomarkers, were both freshly blessed by the field’s governing societies.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in